Detailed analysis of cabozantinib indications and treatment areas

Cabozantinib is a targeted therapy drug that is a tyrosine kinase inhibitor (TKI). Its mechanism of action is mainly by inhibiting the tyrosine kinase activity of multiple targets, thereby interfering with tumor growth, metastasis and angiogenesis at the molecular level. Cabozantinib not only inhibits tumor cell proliferation, but also prevents the formation of tumor-related blood vessels, thereby inhibiting tumor development. Its targets include multiple tyrosine kinases such as MET, VEGFR, and AXL, so it has shown good efficacy in the treatment of various malignant tumors.

Cabozantinib has a wide range of indications and is mainly used to treat a variety of advanced malignant tumors, especially for some refractory tumors and drug-resistant tumors. Specifically, cabozantinib is approved to treat the following tumors:

First, cabozantinib plays an important role in the treatment of advanced renal cell carcinoma (RCC). It is used in patients whose disease has progressed after first-line therapy, such as vascular endothelial growth factor receptor (VEGFR) inhibitors. Studies have shown that cabozantinib can effectively delay disease progression and improve survival rates in these patients.

Secondly, cabozantinib is also used to treat advanced hepatocellular carcinoma (HCC). Cabozantinib offers an effective treatment option for patients with liver cancer who are ineligible for surgery or liver transplantation, especially those with progressive disease. By inhibiting the proliferation and angiogenesis of tumor cells, it can effectively inhibit tumor growth and prolong the progression-free survival of patients.

In addition, cabozantinib also plays a role in the treatment of thyroid cancer, especially in patients with refractory advanced dedifferentiated thyroid cancer (DTC). Dedifferentiated thyroid cancer is a type of thyroid cancer that progresses rapidly and is difficult to treat. The introduction of cabozantinib brings new treatment hope to these patients.

Reference:https://en.wikipedia.org/wiki/Cabozantinib